Ruxolitinib

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Graft-versus-host Disease (GVHD)

Conditions

Graft-versus-host Disease (GVHD)

Trial Timeline

— → —

NCT ID

NCT05722912

About Ruxolitinib

Ruxolitinib is a pre-clinical stage product being developed by Incyte for Graft-versus-host Disease (GVHD). The current trial status is completed. This product is registered under clinical trial identifier NCT05722912. Target conditions include Graft-versus-host Disease (GVHD).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03147742	Pre-clinical	Completed	—	—	Graft-versus-host Disease (GVHD)
NCT04355793	Pre-clinical	Completed	—	—	COVID-19
NCT01730755	Pre-clinical	Completed	—	—	Erythrocytosis, Familial, 2
NCT05722912	Pre-clinical	Completed	—	—	Graft-versus-host Disease (GVHD)
NCT07424222	Phase 1	Recruiting	May 1, 2026	Dec 1, 2028	Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
NCT07356245	Phase 2	Recruiting	Feb 1, 2026	Jan 31, 2027	T-cell Lymphoma
NCT07252050	Phase 1/2	Recruiting	Jan 1, 2026	Nov 19, 2029	Sickle Cell Disease
NCT07085039	Phase 2	Recruiting	Dec 18, 2025	Dec 31, 2028	Castleman's Disease (CD)
NCT05293717	Phase 1/2	Completed	Jul 11, 2022	Dec 31, 2024	Chronic Hand Dermatitis
NCT04908280	Phase 2	Completed	May 4, 2022	Mar 4, 2024	Discoid Lupus Erythematosus
NCT04807777	Phase 2	Terminated	Apr 7, 2022	Oct 4, 2023	Advanced Cutaneous Squamous Cell Carcinoma
NCT04644211	Phase 2	Recruiting	Mar 21, 2022	Jul 1, 2034	Essential Thrombocythemia
NCT04354714	Phase 2	Withdrawn	Jun 30, 2020	Dec 31, 2021	COVID-19
NCT03801434	Phase 2	Recruiting	Nov 15, 2019	Dec 30, 2028	BCR-JAK2 Fusion Protein Expression
NCT03722407	Phase 2	Active	Aug 28, 2019	Jun 1, 2026	Chronic Myelomonocytic Leukemia
NCT03674047	Phase 2	Active	Apr 19, 2019	Dec 1, 2025	Other Cancer
NCT03427866	Phase 2	Completed	Aug 28, 2018	May 19, 2025	Myelofibrosis
NCT03153982	Phase 2	Terminated	Jun 8, 2018	Oct 18, 2023	Head and Neck Squamous Cell Carcinoma
NCT01895842	Phase 1	Completed	Feb 1, 2014	Apr 2, 2019	Leukemia
NCT01776723	Phase 1/2	Completed	Feb 20, 2013	May 10, 2022	Myelomonocytic Leukemia

Competing Products

20 competing products in Graft-versus-host Disease (GVHD)

See all competitors

Product	Company	Stage	Hype Score
Alefacept	Astellas Pharma	Phase 2	52
EQ001 + EQ001 Placebo	Biocon	Phase 1/2	41
SHR0302	Jiangsu Hengrui Medicine	Phase 1	33
Prednisone + Jakavi(ruxolitinib) + Prednisone	Novartis	Phase 2	52
PredEver	Novartis	Phase 2	52
Lifitegrast 5% Ophthalmic Solution + Placebo	Novartis	Phase 1	33
LBH589 + Methylprednisolone	Novartis	Phase 2	52
Panobinostat (LBH589)	Novartis	Phase 1/2	41
Filgrastim	Amgen	Pre-clinical	22
AMG 592	Amgen	Phase 1	32
AMG 592	Amgen	Phase 1	32
BMS-986004 + Sirolimus + Tacrolimus	Bristol Myers Squibb	Phase 1	32
Belumosudil (KD025)	Sanofi	Phase 2	51
Belumosudil 200 mg QD + Belumosudil 200 mg BID + Belumosudil 400 mg QD	Sanofi	Phase 2	51
AAT + Placebo	CSL	Phase 2/3	64
Ruxolitinib + Methylprednisolone	Incyte	Phase 2	49
Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)	Incyte	Phase 3	74
Itacitinib + Corticosteroids	Incyte	Phase 1/2	38
Ruxolitinib	Incyte	Pre-clinical	20
Itacitinib + Corticosteroid	Incyte	Phase 1	30

Other Products from Incyte

ruxolitinib creamApproved

Itacitinib + Placebo + Prednisone + MethylprednisolonePhase 3

Povorcitinib + PlaceboPhase 3

Ruxolitinib Cream + Vehicle CreamPhase 3

Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)Phase 3